Recent Post
Related Posts
POTOMAC, MARYLAND – November 13, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence (“AI”) to develop innovative
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
POTOMAC, MARYLAND November 10, 2025 / IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
POTOMAC, MARYLAND – November 03, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for
POTOMAC, MARYLAND – October 22, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today
POTOMAC, MARYLAND – October 14, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for